Human Genome Epidemiology Literature Finder
Records 1 - 12 (of 12 Records) |
Query Trace: Breast Neoplasms and ERBB3[original query] |
---|
The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study. The Journal of pathology 2015 May . Guerini-Rocco Elena, Hodi Zsolt, Piscuoglio Salvatore, Ng Charlotte Ky, Rakha Emad A, Schultheis Anne M, Marchiò Caterina, da Cruz Paula Arnaud, De Filippo Maria R, Martelotto Luciano G, De Mattos-Arruda Leticia, Edelweiss Marcia, Jungbluth Achim A, Fusco Nicola, Norton Larry, Weigelt Britta, Ellis Ian O, Reis-Filho Jorge |
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies. Breast cancer research : BCR 2017 7 19 (1): 87. Toomey Sinead, Eustace Alexander J, Fay Joanna, Sheehan Katherine M, Carr Aoife, Milewska Malgorzata, Madden Stephen F, Teiserskiene Ausra, Kay Elaine W, O'Donovan Norma, Gallagher William, Grogan Liam, Breathnach Oscar, Walshe Janice, Kelly Catherine, Moulton Brian, Kennedy M John, Gullo Guiseppe, Hill Arnold D, Power Colm, Duke Deirdre, Hambly Niamh, Crown John, Hennessy Bryan |
Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH). PloS one 2018 8 13 (8): e0200996. Coté Damien, Eustace Alex, Toomey Sinead, Cremona Mattia, Milewska Malgorzata, Furney Simon, Carr Aoife, Fay Joanna, Kay Elaine, Kennedy Susan, Crown John, Hennessy Bryan, Madden Steph |
Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer. Therapeutic advances in medical oncology 2018 10 1758835918778297. Elster Naomi, Toomey Sinead, Fan Yue, Cremona Mattia, Morgan Clare, Weiner Gorzel Karolina, Bhreathnach Una, Milewska Malgorzata, Murphy Madeline, Madden Stephen, Naidoo Jarushka, Fay Joanna, Kay Elaine, Carr Aoife, Kennedy Sean, Furney Simon, Mezynski Janusz, Breathhnach Oscar, Morris Patrick, Grogan Liam, Hill Arnold, Kennedy Susan, Crown John, Gallagher William, Hennessy Bryan, Eustace Al |
Genetic Alterations in Benign Breast Biopsies of Subsequent Breast Cancer Patients. Frontiers in medicine 2019 8 6 166. Soysal Savas D, Ng Charlotte K Y, Costa Luigi, Weber Walter P, Paradiso Viola, Piscuoglio Salvatore, Muenst Simo |
LobSig is a multigene predictor of outcome in invasive lobular carcinoma. NPJ breast cancer 2019 7 5 18. McCart Reed Amy E, Lal Samir, Kutasovic Jamie R, Wockner Leesa, Robertson Alan, de Luca Xavier M, Kalita-de Croft Priyakshi, Dalley Andrew J, Coorey Craig P, Kuo Luyu, Ferguson Kaltin, Niland Colleen, Miller Gregory, Johnson Julie, Reid Lynne E, Males Renique, Saunus Jodi M, Chenevix-Trench Georgia, Coin Lachlan, Lakhani Sunil R, Simpson Peter |
Comparison of TCGA and GENIE genomic datasets for the detection of clinically actionable alterations in breast cancer. Scientific reports 2019 2 9 (1): 1482. Kaur Pushpinder, Porras Tania B, Ring Alexander, Carpten John D, Lang Julie |
Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients. International journal of cancer 2019 Feb . Kim Ji-Yeon, Lee Eunjin, Park Kyunghee, Jung Hae Hyun, Park Woong-Yang, Lee Kyung-Hun, Sohn Joohyuk, Lee Keun Seok, Jung Kyung Hae, Kim Jee Hyun, Lee Ki Hyeong, Im Seock-Ah, Park Yeon H |
Identification of novel candidate genes by exome sequencing in Tunisian familial male breast cancer patients. Molecular biology reports 2020 9 47 (9): 6507-6516. Ben Kridis-Rejeb Wala, Ben Ayed-Guerfali Dorra, Ammous-Boukhris Nihel, Ayadi Wajdi, Kifagi Chamseddine, Charfi Slim, Saguem Ines, Sellami-Boudawara Tahia, Daoud Jamel, Khanfir Afef, Mokdad-Gargouri Ra |
Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients. Breast cancer research and treatment 2020 Aug . Skriver Signe Korsgaard, Jensen Maj-Britt, Eriksen Jens-Ole, Ahlborn Lise Barlebo, Knoop Ann Soegaard, Rossing Maria, Ejlertsen Bent, Laenkholm Anne-Vibe |
Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses. BMC cancer 2021 2 21 (1): 199. Huang Chi-Cheng, Tsai Yi-Fang, Liu Chun-Yu, Chao Ta-Chung, Lien Pei-Ju, Lin Yen-Shu, Feng Chin-Jung, Chiu Jen-Hwey, Hsu Chih-Yi, Tseng Ling-Mi |
Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2?+?metastatic breast cancer. Scientific reports 2023 6 13 (1): 9928. Kyoungmin Lee, Jongwon Lee, Jungmin Choi, Sung Hoon Sim, Jeong Eun Kim, Min Hwan Kim, Yeon Hee Park, Jee Hyun Kim, Su-Jin Koh, Kyong Hwa Park, Myoung Joo Kang, Mi Sun Ahn, Kyoung Eun Lee, Hee-Jun Kim, Hee Kyung Ahn, Han Jo Kim, Keon Uk Park, In Hae Pa |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 29, 2024
- Content source: